Buscar
Resultados de la búsqueda
- Farmacovigilancia intensiva en pediatría de nimotuzumab para el tratamiento de tumores gliales malignos
-
... intensiva en pediatría del anticuerpo monoclonal nimotuzumab para el tratamiento de tumores gliales malignos. ... claves: nimotuzumab,tumores gliales malignos, tumores cerebrales pediátricos ...
Ensayos Clínicos - CIMAB - 14/08/2014 - 4:34pm
- CIMAVax EGF in Lung Cancer in PHC. Phase IV
-
... treatment with EGF therapeutic vaccine CIMAvax and / or Nimotuzumab (therapeutic monoclonal antibody hR3). 2. Patients with chronic ...
Clinical Trials - CIM - 05/08/2014 - 3:18pm
- CIMAVaxEGF en Cáncer Pulmón en APS
-
... tratamiento con la vacuna terapéutica CIMAvax EGF y/o Nimotuzumab (Anticuerpo monoclonal terapéutico hR3). 2. Pacientes con ...
Ensayos Clínicos - CIM - 05/08/2014 - 3:17pm
- Racotumomab,Nimotuzumab or Docetaxel in the treatment of the advanced non-small cell lung cancer.
-
... patients with advanced NSCLC treated with Racotumomab or Nimotuzumab, vs Docetaxel after first line treatment oncospecific. ... general condition permits. Group 2 (experimental arm) : Nimotuzumab mAb (200 mg) intravenous (antecubital vein), in 250 ml of saline ...
Clinical Trials - CIM - 26/05/2014 - 3:06pm
- Racotumomab,Nimotuzumab o Docetaxel para el tratamiento de cancer de pulmon de celulas no pequeñas avanzado.
-
... en pacientes con CPCNP avanzado tratados con Racotumomab o Nimotuzumab, vs Docetaxel después de la primera línea de tratamiento ... general del paciente lo permita. Grupo 2 (estudio): AcM Nimotuzumab (200 mg) por vía endovenosa (vena ante cubital), en 250 ml de ...
Ensayos Clínicos - CIM - 26/05/2014 - 2:59pm
- Phase II / III. Nimotuzumab in patients with triple-negative breast cancer.
-
... for the evaluation of the efficacy and safety of using Nimotuzumab in patients with triple-negative breast cancer. Phase II / III. ... arm): Chemotherapy (CT) + CT a dose metronomic + Nimotuzumab: 200 mg intravenously in 250 ml of isotonic saline for 30 minutes. ...
Clinical Trials - CIM - 23/05/2014 - 2:16pm
- Fase II/III Nimotuzumab en cancer de mama triple negativo
-
... la evaluación de la eficacia y la seguridad del uso del nimotuzumab en pacientes con cáncer de mama triple negativo. Fase II/III. ... mama, nimotuzumab, triple negativo, quimioterapia metronomica, eficacia , seguridad ...
Ensayos Clínicos - CIM - 23/05/2014 - 2:15pm
- hR3 en cáncer colorectal metastásico o recurrente
-
... Evaluación del anticuerpo monoclonal Nimotuzumab (h-R3) como monoterapia en pacientes con cáncer colorectal ... Grupo I (Experimental): Nimotuzumab (hR3) 200 mg. Grupo II (Experimental): Nimotuzumab (hR3) 400 mg. ...
Ensayos Clínicos - CIM - 22/11/2013 - 3:45pm
- hR3 in metastatic or recurrent colorectal cancer
-
... Evaluation of Nimotuzumab (hR3) mAb as Monotherapy in patients with metastatic or recurrent ... Group I (Experimental): Nimotuzumab (hR3) 200 mg. Grupo II (Experimental): Nimotuzumab (hR3) 400 mg. ...
Clinical Trials - CIM - 22/11/2013 - 3:44pm
- Intravenous CIGB-128-A in patients with brain tumors (BRATINC Study)
-
... treated with immunotherapy over the last month (except Nimotuzumab®) or those that are receiving other type of specific oncological ... month) in another study, except for phase IV trials with Nimotuzumab®. 10. Sepsis of the Central Nervous System. 11. Severe psychiatric ...
Clinical Trials - CIGB - 08/11/2013 - 11:02am